A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

This study is testing a new drug called PM8002 (which combines an anti-cancer antibody with an anti-blood-vessel agent) together with standard chemotherapy as the first treatment for people with malignant mesothelioma — a rare cancer most often found in the lining of the lungs, usually linked to asbestos exposure. **You may be eligible if:** - You are 18 years or older - You have been diagnosed with malignant mesothelioma confirmed by tissue biopsy, and surgery is not an option - You have not received any prior systemic (whole-body) anti-cancer treatment (or finished adjuvant chemotherapy more than 6 months before your cancer came back) - You have at least one measurable tumor on imaging scans - Your organ function (blood, liver, kidneys) is adequate - You are in reasonably good physical condition (able to carry out light activity) - Your expected survival is at least 12 weeks **You may NOT be eligible if:** - You have active, symptomatic brain or spinal cord metastases - You have had another active cancer within the past 5 years (with some exceptions for easily cured skin cancers) - You have a severe allergy history or known allergy to any component of the study drugs - You have other serious uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.